• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Immunotherapy in Non-Small-Cell Lung Cancer Patients With Performance Status 2: Clinical Decision Making With Scant Evidence.

作者信息

Passaro Antonio, Spitaleri Gianluca, Gyawali Bishal, de Marinis Filippo

机构信息

1European Institute of Oncology, IRCCS, Milan, Italy.

2Brigham and Women's Hospital and Harvard Medical School, Boston, MA.

出版信息

J Clin Oncol. 2019 Aug 1;37(22):1863-1867. doi: 10.1200/JCO.18.02118. Epub 2019 Apr 17.

DOI:10.1200/JCO.18.02118
PMID:30995172
Abstract
摘要

相似文献

1
Immunotherapy in Non-Small-Cell Lung Cancer Patients With Performance Status 2: Clinical Decision Making With Scant Evidence.体能状态为2的非小细胞肺癌患者的免疫治疗：证据匮乏情况下的临床决策
J Clin Oncol. 2019 Aug 1;37(22):1863-1867. doi: 10.1200/JCO.18.02118. Epub 2019 Apr 17.
2
Recent clinical trials of immunotherapy in non-small-cell lung cancer.近期非小细胞肺癌免疫疗法的临床试验。
Immunotherapy. 2019 Apr;11(6):461-466. doi: 10.2217/imt-2019-0021.
3
Common Mechanisms Linking Chronic Obstructive Pulmonary Disease and Lung Cancer.慢性阻塞性肺疾病与肺癌的共同发病机制。
Ann Am Thorac Soc. 2018 Dec;15(Suppl 4):S273-S277. doi: 10.1513/AnnalsATS.201808-537MG.
4
Immune Checkpoint Inhibitor Outcomes for Patients With Non-Small-Cell Lung Cancer Receiving Baseline Corticosteroids for Palliative Versus Nonpalliative Indications.接受基线皮质类固醇治疗以缓解症状和非缓解症状的非小细胞肺癌患者的免疫检查点抑制剂治疗结局。
J Clin Oncol. 2019 Aug 1;37(22):1927-1934. doi: 10.1200/JCO.19.00189. Epub 2019 Jun 17.
5
Chemotherapy-induced immunomodulation in non-small-cell lung cancer: a rationale for combination chemoimmunotherapy.化疗诱导的非小细胞肺癌免疫调节：联合化疗免疫疗法的理论依据
Immunotherapy. 2017 Sep;9(11):913-927. doi: 10.2217/imt-2017-0052.
6
Immunotherapy for non-small cell lung cancer: are we on the cusp of a new era?非小细胞肺癌的免疫疗法：我们正处在一个新时代的边缘吗？
Expert Rev Clin Immunol. 2015;11(8):871-3. doi: 10.1586/1744666X.2015.1054374. Epub 2015 Jun 7.
7
FDA approves breakthrough immunotherapy for patients with non-small-cell lung cancer.美国食品药品监督管理局批准了用于非小细胞肺癌患者的突破性免疫疗法。
Cancer. 2017 Jan 1;123(2):191. doi: 10.1002/cncr.30524.
8
Understanding the Rationale for Immunotherapy in Non-Small Cell Lung Cancer.了解非小细胞肺癌免疫治疗的基本原理。
Semin Oncol. 2015 Oct;42 Suppl 2:S3-10. doi: 10.1053/j.seminoncol.2015.09.016. Epub 2015 Sep 11.
9
Immunotherapy alone or chemo-immunotherapy as front-line treatment for advanced non-small cell lung cancer.免疫疗法单药治疗或化疗联合免疫疗法作为晚期非小细胞肺癌的一线治疗。
Expert Opin Biol Ther. 2019 Mar;19(3):225-232. doi: 10.1080/14712598.2019.1571036. Epub 2019 Jan 25.
10
Chronic obstructive pulmonary disease as a prognostic factor in non-small cell lung cancer.慢性阻塞性肺疾病作为非小细胞肺癌的一个预后因素
Eur J Cardiothorac Surg. 2005 Sep;28(3):505-6; author reply 506. doi: 10.1016/j.ejcts.2005.05.009.

引用本文的文献

1
The Efficacy of First-Line Pembrolizumab Monotherapy in Patients with Metastatic NSCLC Aged ≥70 Years with High PD-L1 (TPS ≥ 50%) Expression: A Multicenter Real-World Study.一线帕博利珠单抗单药治疗在年龄≥70岁、PD-L1高表达（TPS≥50%）的转移性非小细胞肺癌患者中的疗效：一项多中心真实世界研究
Cancers (Basel). 2025 Jun 28;17(13):2190. doi: 10.3390/cancers17132190.
2
Survivorship Challenges and Supportive Care in Lung Cancer.肺癌的生存挑战与支持性护理
Semin Respir Crit Care Med. 2025 Jul 30. doi: 10.1055/a-2649-9311.
3
Determinants of 5-year survival in patients with advanced NSCLC with PD-L1≥50% treated with first-line pembrolizumab outside of clinical trials: results from the Pembro-real 5Y global registry.
在临床试验之外接受一线帕博利珠单抗治疗的PD-L1≥50%的晚期非小细胞肺癌患者5年生存率的决定因素：Pembro-real 5Y全球注册研究结果
J Immunother Cancer. 2025 Feb 4;13(2):e010674. doi: 10.1136/jitc-2024-010674.
4
Real-World Efficacy and Safety of Atezolizumab for Advanced Non-Small Cell Lung Cancer in Japan: A Retrospective Multicenter Analysis.阿替利珠单抗治疗日本晚期非小细胞肺癌的真实世界疗效和安全性：一项回顾性多中心分析
J Clin Med. 2024 Dec 20;13(24):7815. doi: 10.3390/jcm13247815.
5
Survival prognostic factors in nonsmall cell lung cancer patients with simultaneous brain metastases and poor performance status at initial presentation.初始表现为同时发生脑转移且体能状态较差的非小细胞肺癌患者的生存预后因素
Heliyon. 2024 Sep 19;10(18):e38128. doi: 10.1016/j.heliyon.2024.e38128. eCollection 2024 Sep 30.
6
Inclusion, characteristics, and reporting of older adults in FDA registration studies of immunotherapy, 2018-2022.2018-2022 年 FDA 免疫疗法注册研究中纳入的老年人群体的特征和报告情况。
J Immunother Cancer. 2024 Aug 28;12(8):e009258. doi: 10.1136/jitc-2024-009258.
7
The Construction of a Nomogram Using the Pan-Immune-Inflammation Value Combined with a PILE Score for Immunotherapy Prediction Prognosis in Advanced NSCLC.使用全免疫炎症值联合PILE评分构建列线图以预测晚期非小细胞肺癌免疫治疗的预后
Cancer Manag Res. 2024 Jul 2;16:741-751. doi: 10.2147/CMAR.S461964. eCollection 2024.
8
Real-World Data and Evidence in Lung Cancer: A Review of Recent Developments.肺癌的真实世界数据与证据：近期进展综述
Cancers (Basel). 2024 Apr 4;16(7):1414. doi: 10.3390/cancers16071414.
9
The S-REAL study: Spanish real-world data on unresectable stage III NSCLC patients treated with durvalumab after chemoradiotherapy.S-REAL 研究：durvalumab 治疗不可切除 III 期 NSCLC 患者的西班牙真实世界数据，这些患者在放化疗后接受了 durvalumab 治疗。
Clin Transl Oncol. 2024 Jul;26(7):1779-1789. doi: 10.1007/s12094-024-03404-9. Epub 2024 Mar 21.
10
Utility of contrast-enhanced MRI radiomics features combined with clinical indicators for predicting induction chemotherapy response in primary central nervous system lymphoma.对比增强 MRI 放射组学特征联合临床指标预测原发性中枢神经系统淋巴瘤诱导化疗反应的价值。
J Neurooncol. 2024 Feb;166(3):451-460. doi: 10.1007/s11060-023-04554-6. Epub 2024 Feb 3.